{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:02:41Z","timestamp":1789635761977,"version":"4.0.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04953-2","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:17:27Z","timestamp":1789633047000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Main pulmonary artery enlargement during bevacizumab therapy in KRAS-mutant metastatic colon cancer"],"prefix":"10.1007","volume":"96","author":[{"given":"Mehmet Fatih","family":"Ozbay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fikret","family":"Atl\u0131m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sertac","family":"Vurgun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Hunur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse","family":"Keven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eren","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sema Sezgin","family":"G\u00f6ksu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Karaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"issue":"23","key":"4953_CR1","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335\u20132342","journal-title":"N Engl J Med"},{"issue":"12","key":"4953_CR2","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, D\u00edaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26(12):2013\u20132019","journal-title":"J Clin Oncol"},{"issue":"5706","key":"4953_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706):58\u201362","journal-title":"Science"},{"issue":"5","key":"4953_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3(5):391\u2013400","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"4953_CR5","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","volume":"25","author":"BJ Giantonio","year":"2007","unstructured":"Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25(12):1539\u20131544","journal-title":"J Clin Oncol"},{"issue":"1","key":"4953_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna J, Sastre J, Arnold D et al (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14(1):29\u201337","journal-title":"Lancet Oncol"},{"issue":"8","key":"4953_CR7","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27(8):1386\u20131422","journal-title":"Ann Oncol"},{"issue":"5","key":"4953_CR8","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/annonc\/mdn713","volume":"20","author":"H Izzedine","year":"2009","unstructured":"Izzedine H, Ederhy S, Goldwasser F et al (2009) Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 20(5):807\u2013815","journal-title":"Ann Oncol"},{"issue":"2","key":"4953_CR9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","volume":"49","author":"X Zhu","year":"2007","unstructured":"Zhu X, Wu S, Dahut WL, Parikh CR (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49(2):186\u2013193","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"4953_CR10","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/annonc\/mdm550","volume":"19","author":"JJ Mourad","year":"2008","unstructured":"Mourad JJ, des Guetz G, Debbabi H, Levy BI (2008) Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 19(5):927\u2013934","journal-title":"Ann Oncol"},{"issue":"1","key":"4953_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1089\/ars.2013.5244","volume":"20","author":"S Lankhorst","year":"2014","unstructured":"Lankhorst S, Kappers MH, van Esch JH, van den Danser AH (2014) Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress. Antioxid Redox Signal 20(1):135\u2013145","journal-title":"Antioxid Redox Signal"},{"issue":"5","key":"4953_CR12","first-page":"534","volume":"30","author":"HY Small","year":"2014","unstructured":"Small HY, Montezano AC, Rios FJ, Savoia C, Touyz RM (2014) Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. Can J Cardiol 30(5):534\u2013543","journal-title":"Can J Cardiol"},{"issue":"16","key":"4953_CR13","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/jnci\/djm086","volume":"99","author":"FA Scappaticci","year":"2007","unstructured":"Scappaticci FA, Skillings JR, Holden SN et al (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99(16):1232\u20131239","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"4953_CR14","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1200\/JCO.2010.31.9129","volume":"29","author":"TK Choueiri","year":"2011","unstructured":"Choueiri TK, Mayer EL, Je Y et al (2011) Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 29(6):632\u2013638","journal-title":"J Clin Oncol"},{"issue":"13","key":"4953_CR15","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.115.018347","volume":"133","author":"J Herrmann","year":"2016","unstructured":"Herrmann J, Yang EH, Iliescu CA et al (2016) Vascular toxicities of cancer therapies: The old and the new \u2014 An evolving avenue. Circulation 133(13):1272\u20131289","journal-title":"Circulation"},{"issue":"2","key":"4953_CR16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1096\/fj.00-0343com","volume":"15","author":"L Taraseviciene-Stewart","year":"2001","unstructured":"Taraseviciene-Stewart L, Kasahara Y, Alger L et al (2001) Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 15(2):427\u2013438","journal-title":"FASEB J"},{"issue":"4","key":"4953_CR17","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1165\/rcmb.2014-0045TR","volume":"51","author":"NF Voelkel","year":"2014","unstructured":"Voelkel NF, Gomez-Arroyo J (2014) The role of vascular endothelial growth factor in pulmonary arterial hypertension. The angiogenesis paradox. Am J Respir Cell Mol Biol 51(4):474\u2013484","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"3","key":"4953_CR18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/path.953","volume":"195","author":"RM Tuder","year":"2001","unstructured":"Tuder RM, Chacon M, Alger L et al (2001) Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol 195(3):367\u2013374","journal-title":"J Pathol"},{"issue":"5","key":"4953_CR19","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1183\/09031936.00188611","volume":"40","author":"L Savale","year":"2012","unstructured":"Savale L, Chaumais MC, Cottin V et al (2012) Pulmonary hypertension associated with benfluorex exposure. Eur Respir J 40(5):1164\u20131172","journal-title":"Eur Respir J"},{"issue":"2","key":"4953_CR20","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1378\/chest.09-1140","volume":"137","author":"DB Badesch","year":"2010","unstructured":"Badesch DB, Raskob GE, Elliott CG et al (2010) Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 137(2):376\u2013387. https:\/\/doi.org\/10.1378\/chest.09-1140","journal-title":"Chest"},{"issue":"17","key":"4953_CR21","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","volume":"125","author":"D Montani","year":"2012","unstructured":"Montani D, Bergot E, G\u00fcnther S et al (2012) Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125(17):2128\u20132137","journal-title":"Circulation"},{"issue":"2","key":"4953_CR22","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ygyno.2009.08.003","volume":"115","author":"M Liotta","year":"2009","unstructured":"Liotta M, Rose PG, Escobar PF (2009) Pulmonary hypertension in two patients treated with bevacizumab for recurrent ovarian cancer. Gynecol Oncol 115(2):308\u2013309","journal-title":"Gynecol Oncol"},{"issue":"1","key":"4953_CR23","doi-asserted-by":"publisher","first-page":"11524","DOI":"10.1038\/s41598-023-38377-2","volume":"13","author":"T Kondo","year":"2023","unstructured":"Kondo T, Fujiwara K, Nakagawa M et al (2023) Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patients. Sci Rep 13(1):11524. https:\/\/doi.org\/10.1038\/s41598-023-38377-2","journal-title":"Sci Rep"},{"issue":"1","key":"4953_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1161\/CIRCIMAGING.111.968610","volume":"5","author":"QA Truong","year":"2012","unstructured":"Truong QA, Massaro JM, Rogers IS et al (2012) Reference values for normal pulmonary artery dimensions by noncontrast cardiac computed tomography: the Framingham Heart Study. Circ Cardiovasc Imaging 5(1):147\u2013154","journal-title":"Circ Cardiovasc Imaging"},{"issue":"5","key":"4953_CR25","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1378\/chest.113.5.1250","volume":"113","author":"RT Tan","year":"1998","unstructured":"Tan RT, Kuzo R, Goodman LR, Siegel R, Haasler GB, Presberg KW (1998) Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease. Chest 113(5):1250\u20131256","journal-title":"Chest"},{"issue":"1","key":"4953_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jcct.2017.12.001","volume":"12","author":"QA Truong","year":"2018","unstructured":"Truong QA, Bhatia HS, Szymonifka J et al (2018) A four-tier classification system of pulmonary artery metrics on computed tomography for the diagnosis and prognosis of pulmonary hypertension. J Cardiovasc Comput Tomogr 12(1):60\u201366. https:\/\/doi.org\/10.1016\/j.jcct.2017.12.001","journal-title":"J Cardiovasc Comput Tomogr"},{"issue":"1","key":"4953_CR27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Gali\u00e8","year":"2016","unstructured":"Gali\u00e8 N, Humbert M, Vachiery JL et al (2016) 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 37(1):67\u2013119","journal-title":"Eur Heart J"},{"issue":"850","key":"4953_CR28","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1259\/bjr.71.850.10211060","volume":"71","author":"PD Edwards","year":"1998","unstructured":"Edwards PD, Bull RK, Coulden R (1998) CT measurement of main pulmonary artery diameter. Br J Radiol 71(850):1018\u20131022","journal-title":"Br J Radiol"},{"issue":"25","key":"4953_CR29","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1161\/CIRCULATIONAHA.109.927681","volume":"121","author":"K Abe","year":"2010","unstructured":"Abe K, Toba M, Alzoubi A et al (2010) Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 121(25):2747\u20132754","journal-title":"Circulation"},{"issue":"6","key":"4953_CR30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00395-020-0811-5","volume":"115","author":"MP Winter","year":"2020","unstructured":"Winter MP, Sharma S, Altmann J et al (2020) Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension. Basic Res Cardiol 115(6):58. https:\/\/doi.org\/10.1007\/s00395-020-0811-5","journal-title":"Basic Res Cardiol"},{"issue":"1","key":"4953_CR31","doi-asserted-by":"publisher","first-page":"2004455","DOI":"10.1183\/13993003.04455-2020","volume":"57","author":"M Remy-Jardin","year":"2021","unstructured":"Remy-Jardin M, Ryerson CJ, Schiebler ML et al (2021) Imaging of pulmonary hypertension in adults: a position paper from the Fleischner Society. Eur Respir J 57(1):2004455","journal-title":"Eur Respir J"},{"issue":"1","key":"4953_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1532-429X-14-40","volume":"14","author":"AJ Swift","year":"2012","unstructured":"Swift AJ, Rajaram S, Condliffe R et al (2012) Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension. J Cardiovasc Magn Reson 14(1):40","journal-title":"J Cardiovasc Magn Reson"},{"issue":"36","key":"4953_CR33","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D et al (2016) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J 37(36):2768\u20132801","journal-title":"Eur Heart J"},{"issue":"41","key":"4953_CR34","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43(41):4229\u20134361","journal-title":"Eur Heart J"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04953-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04953-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04953-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:17:32Z","timestamp":1789633052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04953-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4953"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04953-2","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"10 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Akdeniz University Medical Scientific Research Ethics Committee (Decision No. TBAEK-131, dated 26 February 2026) and was conducted in accordance with the Declaration of Helsinki. Given the retrospective design and the use of routinely collected clinical and imaging data, the requirement for individual informed consent was waived.","order":2,"name":"Ethics","label":"Compliance with ethical standards","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"108"}}